Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 13/20 | 0.50 |
| ▸ | JAK2 | O60674 | 3/20 | 0.49 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 2/20 | 0.48 |
| ▸ | CDK1 | P06493 | 1/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.48 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.48 |
| ▸ | JAK3 | P52333 | 2/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | BCR | P11274 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34464867 | 0.91 | CAMK2D (0.53) | SYKJAK2CAMK2DCDK2CDK1 | |
| SCHEMBL34464745 | 0.90 | JAK2 (0.56) | SYKJAK2CAMK2DCDK2JAK3 | |
| SCHEMBL34464820 | 0.90 | JAK2 (0.54) | SYKJAK2CAMK2DCDK2CDK1 | |
| Formic Acid SCHEMBL34464810 | 0.86 | JAK2 (0.51) | SYKJAK2CAMK2DCDK2CDK1 | |
| SCHEMBL34464869 | 0.85 | JAK2 (0.47) | SYKJAK2CAMK2DCDK2JAK3 | |
| SCHEMBL34464765 | 0.83 | ABL1 (0.60) | SYKJAK2CAMK2DCDK2CCNA2 | |
| SCHEMBL34464821 | 0.83 | CAMK2D (0.56) | JAK2CAMK2DCDK2CDK1CCNA2 | |
| SCHEMBL34464794 | 0.80 | JAK2 (0.56) | SYKJAK2CAMK2DCDK2JAK3 | |
| SCHEMBL34464802 | 0.79 | JAK2 (0.53) | JAK2CAMK2DCDK2CDK1JAK3 | |
| SCHEMBL34464746 | 0.79 | JAK2 (0.67) | SYKJAK2CAMK2DCDK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109690-A1 | HDAC6 INHIBITORS AND METHOD OF THEIR USE | BAERENKRAFT THERAPEUTICS LLC (US) | 2026-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109690-A1 | HDAC6 INHIBITORS AND METHOD OF THEIR USE | HDAC6, HDAC3, HDAC1 | SYK 4557/4885JAK2 2639/4885CAMK2D 378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.